A rare case of nephrotic syndrome and arterial thrombosis following long-term rifampicin therapy.

Satish Kumar Basattikoppalu Puttegowda, Pooja Anjanappa, Tejaswi Prithviraj Hadya Krishna, Yogendra Shrestha

Abstract read

In one paragraph

Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Satish Kumar Basattikoppalu PuttegowdaDepartment of Pharmacy Practice, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B.G. Nagara, 571448, Mandya, Karnataka, India.ORCID http://orcid.org/0000-0001-9475-0969

Pooja AnjanappaDepartment of Pharmacy Practice, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B.G. Nagara, 571448, Mandya, Karnataka, India.ORCID http://orcid.org/0009-0000-0534-3780

Tejaswi Prithviraj Hadya KrishnaDepartment of Psychiatry, Adichunchanagiri Institute of Medical Sciences (AIMS), Adichunchanagiri University, B.G. Nagara, 571448, Mandya, Karnataka, India.ORCID http://orcid.org/0009-0009-1916-7293

Yogendra ShresthaDepartment of Pharmacy Practice, School of Pharmacy, Faculty of Pharmacy, Parul University, 391760, Vadodara, Gujarat, India. dryogendrastha@gmail.com.ORCID http://orcid.org/0000-0003-3032-5802

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although rifampicin is one of the main drugs in the treatment of tuberculosis, its potential for causing nephrotoxic reactions may lead to renal injury. In this paper, we present a 23-year-old man who was treated for pulmonary tuberculosis and who developed a nephrotoxic syndrome caused by rifampicin. This syndrome was defined by abdominal distension due to fluid retention, swelling in both legs, nephrotic range proteinuria and biopsy findings showing tubular atrophy and interstitial fibrosis. The nephrotoxicity developed after a prolonged, uninterrupted course of treatment with rifampicin. The patient was successfully treated for nephrotoxicity with corticosteroids, diuretics, albumin infusion and antihypertensive agents. We emphasize the need for clinicians to be aware of the risk of rifampicin nephrotoxicity, particularly in patients with pre-existing renal impairment.

Indexed as

Arterial thrombosisChronic interstitial nephritisNephrotic syndromeNephrotoxicityRifampicin

Identifiers

PMID41896343

DOI10.1007/s40121-023-00761-w

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.